Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 ...
Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in people 4 months and over.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback